3 years to triple, according to this list to buy pharmaceutical stocks, wages doubled is not a matter!

Guide: One year, research and development strength list of corporate earnings far greater than the industry? Capital markets have long been popular with the phrase, "there is medicine and wine, what life wants", meaning that when the capital market is not good, "take medicine, drink, buy insurance" as the investment of the best choice, by the majority of shareholders recognized.
Just like this "new crown epidemic" outbreak, the capital market has formed an unprecedented impact, the real economy suffered an unprecedented blow at the same time, the development of the industry has also stalled, the market value of the relevant listed companies fell sharply is not uncommon.
, on the other hand, it is in this basic environment, the pharmaceutical industry and the brewing industry against the current, but become the largest black horse since the start of 2020! So how much more "pharmaceutical manufacturing" in capital markets will rise in 2019-2020 than in other sectors, but no data will be available.
Just in time for next month, the "2020 China Drug Research and Development Strength Rankings" series, published by The Drug Intelligence Network, will be announced at its "PDI Conference", also with the top 50 representatives of last year's research and development strength rankings, comparing the gap between the list's corporate earnings and the "pharmaceutical manufacturing industry and major indices", the results are surprising.
Relevant reporters also interviewed Li Tianquan, co-founder of Drug Intelligence Network, according to its statement, when a large number of funds and securities companies asked Li to recommend the pharmaceutical industry's dark horse stocks, in addition to the public familiar with Hengrui, Shanghai Medicine, Fosun and other first-tier enterprises, for the second echelon, whether investors or institutions, are "pharmaceutical enterprise potential" of the determinants know very little, not to mention which enterprises will break out in the near future? It is precisely because of this demand, Li Tianquan and his team dug deep into the research and development-related data of major pharmaceutical enterprises, and finally gathered into the previous "pharmaceutical research and development strength leaderboard", hoping to help the market to explore innovative "black horse enterprises" for the cause of pharmaceutical innovation brick and tile.
statistics from June 21, 2019 to date, the major major indices and pharmaceutical manufacturing industry data, it is easy to know that the one-year yield and the yield to date are "pharmaceutical manufacturing", respectively, reached 32.94 percent, 52.54 percent, basically ahead of all indices.
that the pharmaceutical industry in 2019-2020 to enhance a huge, high-gloss moment often accompanied by its body.
the same pattern, the returns of the top 50 companies in the 2019 research and development strength rankings apply equally, not only to easily compare the gap with the pharmaceutical manufacturing industry, but also to share the final causes of its phenomenon.
, the average one-year yield of the top 50 companies on the list was 49.58 percent, up 16.64 percent, 50.84 percent and 50.84 percent, respectively, compared with the pharmaceutical manufacturing industry, the Shanghai Composite Index and the Shenzhen Composite Index. 22.58 per cent, with a yield of 68.22 per cent so far, an increase of 15.68 per cent, 54.01 per cent and 19.44 per cent respectively over the pharmaceutical manufacturing industry, the Shanghai Composite Index and the Shenzhen Composite Index.
a simple example, based on the above one-year rate of return, Xiaoming at the beginning of the list to invest 10W average distribution to the top 50 enterprises, one year after the total value of its assets will be 15W, three years later the total value of assets is increased to 33.8W, the net profit reached 23.8W, the average monthly income of about 6600 yuan.
for Xiaoming, who earns 6,000 a month, the return on investment has succeeded in exceeding his monthly salary.
that the return on investment in the pharmaceutical manufacturing industry is greater than the general index of the industry, and stable growth.
2. The return on corporate capital in the pharmaceutical research and development strength ranking is higher than the average of the pharmaceutical manufacturing industry, and has grown steadily.
capital markets take into account the potential of enterprises, not limited to their financial data revenue, profits and so on.
is whether it can bring new enterprise value-added for a long time to come, research and development strength as one of the most important factors, the more valued in the future.
Therefore, as an investor, in order to maximize the return on investment, the pharmaceutical manufacturing industry in the strong research and development of enterprises will be its choice, without the relative increase in income, but also has a strong stability, which will be interpreted in later articles.
Today, September 10-11, 2020, under the guidance of China Pharmaceutical University, China Pharmaceutical Enterprise Management Association, Chongqing Economic and Information Technology Commission, Chongqing Economic and Technological Development Zone Management Committee, Chongqing Pharmaceutical Society, Pharmaceutical Network, China Pharmaceutical Industry Magazine, China Pharmacy hosted the "2020 Health Industry High-Quality Development Conference and the 5th China Pharmaceutical Research and Development - Innovation Summit (PDI)" will be held in Chongqing, when the conference will unveil a new "2020 China Pharmaceutical Research and Development Comprehensive Strength Ranking."
undoubtedly, the new list largely suggests that the latest pharmaceutical research and development enterprise layout changes, as investors, will also be a great opportunity to lay out investment, and as a market institution, the list content will also be an important reminder of the choice of high-quality enterprises.
recommended reading: 1. A shares of 13 pharmaceutical companies market value of more than 100 billion! "Junshi" listed on the first day of market value of more than 251 pharmaceutical companies! 2.10 years to see the "big bull market"! A-shares a day 144 enterprises rose and stopped, pharmaceutical is expected to create another miracle 3.16 Chinese pharmaceutical companies into the Forbes 2020 Global Listed Enterprises 2000, China Pharmaceutical Holdings, Shanghai Pharmaceuticals, Hengrui ... 4. High-end generic drugs in the A-shares out of the blue! Berry Pharma is listed today.